COGNITION THERAPEUTICS INC - Common Stock, par value $0.001 per share (CGTX)

CUSIP: 19243B102

Q2 2026 13F Holders as of 30 Jun 2026

Security type / class
Equity / Common Stock, par value $0.001 per share
Total 13F shares
43,776
Total 13F value
$50,343
Holder snapshot 5 signals
Share change
+6,684
SEC-reported price per share
$1.15
Number of holders
2
Value change
+$7,687
Number of buys
2
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
87,819,638

Security key

19243B102

Report period

Q2 2026

Institutions

2

Top holders

2

CGTX full security history Ownership snapshot Full 13F holder table Previous quarter: Q1 2026 COGNITION THERAPEUTICS INC SEC filings COGNITION THERAPEUTICS INC company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of CGTX - COGNITION THERAPEUTICS INC - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
BIOS Memory SPV I, LP
Disclosed value leader
BIOS Memory SPV I, LP
Comparable rows
15/15
Latest evidence
17 Jun 2026
13D/G 3/4/5 13F Lead comparable stake: 6.9% 13D/G row: BIOS Memory SPV I, LP Showing 1-6 of 15 holder rows.

Quick read

BIOS Memory SPV I, LP leads the comparable SEC ownership view at 6.9%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens BIOS Memory SPV I, LP's linked filing trail.
Comparable ownership Top 5
BIOS Memory SPV I, LP 6.9%
Aaron G.l. Fletcher 6.9%
BIOS Advisors GP, LLC 6.9%
BIOS Capital Management, LP 6.9%
Bios Equity Partners II, LP 6.9%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
BIOS Memory SPV I, LP
13D/G 3/4/5
AARON G.L. FLETCHER · Director, 10%+ Owner
13D/G 3/4/5
6.9%
$15,027,696
6,059,555 shares
 $0 19 Sep 2025
Aaron G.l. Fletcher
3/4/5
Director, 10%+ Owner
3/4/5
6.9%
$4,618,687
6,081,229 shares
 — 17 Jun 2026
BIOS Advisors GP, LLC
3/4/5
Director, 10%+ Owner
3/4/5
6.9%
$4,618,687
6,081,229 shares
 — 17 Jun 2026
BIOS Capital Management, LP
3/4/5 13F
Director, 10%+ Owner · Company
3/4/5 13F
6.9%
$4,618,687
6,081,229 shares
 — 17 Jun 2026
Bios Equity Partners II, LP
3/4/5
Director, 10%+ Owner
3/4/5
6.9%
$4,618,687
6,081,229 shares
 — 17 Jun 2026
Bios Equity Partners, LP
3/4/5
Director, 10%+ Owner
3/4/5
6.9%
$4,618,687
6,081,229 shares
 — 17 Jun 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
2
Shares
43,776
Rows available
2
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2026 vs Q1 2026 Across Filers

Q1 2026 holders
74
Q2 2026 holders
2
Holder diff
-72
Investor Q1 2026 Shares Q2 2026 Shares Share Diff Share Chg % Q1 2026 value Q2 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .